Hook & thesis
TG Therapeutics has moved beyond the binary clinical-stage narrative and is now behaving like a commercial biopharma: consistent sequential revenue growth from BRIUMVI, upward guidance, improving operating metrics and what management describes as a sizable non-dilutive financing that materially extends the runway. Those elements together justify taking a constructive, risk-managed long position while the market continues re-rating the shares for durable commercial traction.
Practically: BRIUMVI sales showed strong early traction in 2025, management lifted full-year revenue guidance toward $585 million, the company posts positive EPS and attractive return metrics, and the technical picture (RSI near 68, price above 20/50 SMAs) favors continuation. Add a $500 million non-dilutive capital infusion and you get a setup where upside to the 52-week high near $46.48 is credible within a mid-term window while downside is capped by clear technical support.
What the company does and why the market should care
TG Therapeutics is a biopharmaceutical company focused on B-cell malignancies and autoimmune diseases; its commercial engine today is BRIUMVI, an approved multiple sclerosis therapy. The market cares because BRIUMVI has moved from approval to monetization: management reported $119.7 million in U.S. net BRIUMVI sales in Q1 2025 and a subsequent quarter of rapid growth that led the company to raise full-year revenue guidance to about $585 million. That transition from promise to realized revenue is the single biggest fundamental driver of the stock today.
Concrete numbers that matter
- Market cap: roughly $5.64 billion.
- Reported EPS (most recent metric shown): $2.80, implying a trailing price-to-earnings near 12.6.
- Price-to-sales roughly 9.15 and EV/EBITDA ~47.1, reflecting high revenue multiple driven by strong margin profile and low net leverage.
- Return on equity about 69% and return on assets about 42% - both unusually high and indicative of operational leverage now that commercial sales are meaningful.
- Debt-to-equity moderate at 0.38, and enterprise value about $5.81 billion.
- Recent commercial reads: Q1 2025 U.S. BRIUMVI net sales $119.7 million and Q2 2025 sales were up 91% year-over-year; full-year revenue guidance was raised to ~$585 million.
Why valuation looks reasonable vs. the opportunity
At a $5.64 billion market cap and a P/E of ~12.6, the stock is priced like a company with predictable earnings, while its price-to-sales and EV/EBITDA remain elevated because revenue is concentrated and growth expectations are high. That apparent discrepancy is actually a practical reflection of a company transitioning from clinical-stage multiples to commercial multiples: earnings have started to flow, but revenue upside from broader MS adoption, dosing optimizations and new formulations (subcutaneous BRIUMVI) could justify re-rating. In short, you are paying for growth, but today's earnings and the recently announced non-dilutive capital reduce the funding overhang that previously justified a higher discount.
Technicals and market structure
- Price is trading above its 10-, 20-, and 50-day simple averages ($34.22, $33.02, $30.77 respectively), with 9- and 21-day EMAs similarly supportive.
- RSI sits around 68, indicating bullish near-term momentum but not extreme overbought conditions.
- Short interest has been meaningful historically and the most recent days-to-cover readings are in the low-to-mid teens; that creates asymmetric upside if sentiment flips because covering can add fuel to moves higher.
Trade plan (actionable)
Recommendation: Initiate a long position at an exact entry of $35.42. Set a stop loss at $30.00 to protect capital if the trade fails. Primary target: $46.48 (the 52-week high). Time horizon: mid term (45 trading days).
Rationale for horizon: the mid-term window (45 trading days) captures two important dynamics: (1) the market's digesting of continued BRIUMVI sales momentum and any commercial program updates (subcutaneous formulation/dosing optimizations) and (2) the potential positive sentiment effects from the company's awareness campaigns and capital stability narrative. The stop at $30.00 sits below the 50-day SMA (~$30.77) and under prior consolidation levels, providing a clean technical invalidation point. Targeting the 52-week high is sensible: it is a market-validated level and allows the trade to capture the rerating move without requiring new fundamental breakthroughs.
Position sizing: limit initial exposure to a size that risks no more than 1-2% of portfolio capital to the stop. Biotech remains binary, and while the financing reduces dilution risk, headline events can still produce sharp moves.
Catalysts to drive the trade
- Continued BRIUMVI sales beats and upward guidance revisions. Management has already lifted full-year guidance toward $585 million; another data point in line or above consensus would reinforce the thesis.
- Progress on new formulations and dosing improvements (subcutaneous BRIUMVI) that expand prescriber preference and patient convenience.
- Commercial awareness initiatives and patient outreach (high-profile campaigns can accelerate adoption curves in MS).
- Use of the reported $500 million non-dilutive capital to fund expansion rather than equity issuance; this lowers the risk of shareholder dilution and supports multiple expansion.
Risks and counterarguments
- Commercial execution risk: Strong early sales do not guarantee sustained uptake. Payer dynamics, prescriber switching, or competing label changes could slow adoption and compress forward estimates.
- Regulatory or labeling setbacks: Any negative communications about safety, label restrictions or adverse event profiles could quickly reverse investor enthusiasm and compress the multiple.
- Sentiment and liquidity risk: Despite improving fundamentals, TG Therapeutics carries a meaningful short base and episodic large-volume trading; adverse headlines can be amplified by momentum-driven sellers.
- Valuation fragility: Price-to-sales and EV/EBITDA are elevated; if revenue growth stalls, the current multiple could be hard to sustain and earnings may not be enough to support the present market cap.
- Financing execution risk: While non-dilutive capital is positive, the terms and associated covenants (if any) could constrain operational flexibility. Any misinterpretation or additional debt-like obligations would change the risk profile.
Counterargument: A cautious investor could reasonably argue TG Therapeutics is already priced for perfection: commercial traction is early and concentrated in a single product, and multiples (price-to-sales and EV/EBITDA) imply further expansion. That view has merit and is why the stop is placed below structural support; if new data show slowing growth or a pushback from payers, this stock can reprice quickly.
What would change my mind
I would materially revise a bullish stance if any of the following occur: (1) sequential BRIUMVI sales fall meaningfully below street expectations or management withdraws guidance; (2) new safety or label constraints emerge; (3) the supposed $500 million capital access proves tied to onerous terms that limit growth investment; or (4) price closes decisively below $30.00 on volume, invalidating the technical base and suggesting renewed downside focus. Conversely, repeated revenue beats, margin expansion and visible uptake outside core cohorts would make me more aggressive and push my target higher.
Bottom line
TG Therapeutics is no longer only a pipeline story: it is a commercial story with early, visible revenue and improving profitability metrics. The combination of operational execution, stronger cash visibility from non-dilutive capital and a clean technical setup make a disciplined swing-long logical here at an entry of $35.42, a stop at $30.00 and a 52-week high target of $46.48 over a mid-term 45 trading day horizon. Size the position with strict risk controls and re-evaluate aggressively if sales momentum stalls or funding terms prove restrictive.
Trade mechanics recap: Entry = $35.42 | Stop = $30.00 | Target = $46.48 | Horizon = mid term (45 trading days)